INV501

INV501 is a small molecule drug development program focused on advancing a promising, orally available, immune-activating compound series aimed at targeting tumors with low immunogenicity.

Currently in preclinical development, INV501 is developing toward IND-enabling studies for its clinical candidate, A2-1009. Through a screening process designed to identify compounds capable of enhancing T-cell activity in an antigen-specific way, a novel class of substances was discovered. Among these, A2-1009 emerged as the lead clinical candidate, demonstrating robust in vivo tumor growth control across multiple solid tumor models and a favorable pharmacokinetic and safety profile.

INV441

INV441 is the lead program of our EPiC cell therapy platform, currently in development for the treatment of glioblastoma, an aggressive and deadly brain tumor representing one of the most urgent unmet needs in oncology.

INV441 utilizes our proprietary rapid cell-processing technology to transiently modify tumor-infiltrating lymphocytes (TILs) via small interfering RNA (siRNA)-mediated silencing of Cbl-b, a key intracellular checkpoint that negatively regulates T-cell activation. By inhibiting Cbl-b, TILs gain enhanced resistance to the immunosuppressive cues of the tumor microenvironment (TME), leading to robust antitumor immunity and increased cytotoxic activity against glioblastoma cells.
Following successful completion of preclinical studies, INV441 is now advancing into a first-in-human clinical trial at the Dana-Farber Cancer Institute in Boston, USA.

APN401

APN401 is the first program of our EPiC cell-therapy platform, currently undergoing Phase 1 clinical evaluation in patients with a wide range of solid tumors.

This individualized immunotherapy leverages our proprietary rapid cell-processing technology to manufacture a patient-specific product derived from autologous peripheral blood mononuclear cells (PBMCs). Using a transient small interfering RNA (siRNA) approach, Cbl-b, a central intracellular immune checkpoint, is selectively silenced in PBMCs. This targeted modulation enhances T-cell activation and promotes the development of tumor-reactive immune effector cells.

APN401 is administered in multiple treatment cycles, each utilizing freshly isolated PBMCs. It is designed to amplify the pool of functional immune cells, and overcome adaptive resistance mechanisms within the tumor microenvironment.

In 2024 we successfully completed the treatment of patients in a Phase 1 trial, demonstrating the technical and clinical feasibility of integrating our EPiC platform into routine clinical workflows.

This study further confirmed that both single and multiple-dose infusions of APN401 are well tolerated, with no serious adverse events observed.

INV451

INV451 is an early-stage preclinical program within our EPiC cell therapy platform, focused on the development of transient CAR immune cells for the treatment of various solid tumors.

This program leverages our rapid cell-processing technology to transiently modify immune cells by introducing mRNA encoding a chimeric antigen receptor (CAR). Additionally, the co-delivery of siRNA targeting Cbl-b enhances the cells’ resistance to the immunosuppressive signals present in the TME, resulting in a stronger antitumor response and increased cytotoxicity against tumors expressing the undisclosed CAR-antigen.